ARQT vs BMY
ARQT: Arcutis Biotherapeutics is a commercial-stage dermatology company delivering innovative, targeted treatments for immune-mediated skin conditions. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | ARQT | BMY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $24.49 | $59.58 | |
| Market cap | $3.1B | $121.7B | |
| P/E as of 2026-10-08 | 114.17 | 13.12 | BMY lower |
| Net margin FY2025, SEC XBRL | -4.3% | +14.6% | BMY higher |
| Operating margin FY2025, SEC XBRL | -3.3% | n/a | |
| ROE FY2025, SEC XBRL | -8.5% | +38.2% | BMY higher |
| ROA FY2025, SEC XBRL | -3.7% | +7.8% | BMY higher |
| Debt / equity as of 2026-09-03 | 0.49 | 1.93 | ARQT lower |
| Revenue growth (YoY) as of 2026-09-03 | +76.1% | +3.1% | ARQT higher |
| Revenue CAGR (3y) SEC XBRL | +367.3% | +1.4% | ARQT higher |
| Dividend yield as of 2026-09-03 | n/a | +4.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | BMY higher |
| Beta as of 2026-09-03 | 1.19 | 0.25 | |
| 1-year return as of 2026-10-08 close | +15.3% | +33.8% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.